JAMA Network Open:社交媒体招募癌症患者?或许时机尚早

2021-01-20 医药魔方 医药魔方

根据2020年12月28日在线发表在《JAMA Network Open》(IF:5.03)上的一项调查结果,大多数癌症临床试验小组的研究人员基本上认为社交媒体可以为患者招募带来福音,但与此同时,人们

根据2020年12月28日在线发表在《JAMA Network Open》(IF:5.03)上的一项调查结果,大多数癌症临床试验小组的研究人员基本上认为社交媒体可以为患者招募带来福音,但与此同时,人们并不完全相信这一过程。

这项调查是在美国西南肿瘤协作组(SWOG)癌症研究网络所资助的主要研究者或合作研究者中进行的,共有92位受访者。社交媒体定义为电子通讯的形式,例如社交网络和博客网站,用户可以通过这些网站共享信息、想法和其他内容,包括Twitter、Facebook、Instagram、LinkedIn、YouTube等。

多数人认为,社交媒体可以帮助患者对临床试验提高意识(86%),加深理解(82%)和拓宽可及性渠道(75%)。

图:研究者认为社交媒体招募患者的好处和局限(a表示存在统计学显着性差异)

与此同时,许多临床医生和研究人员担心社交媒体平台上虚假、不正确或不完整信息的传播,可能会导致相关风险(60%)乃至对试验的错误理解(58%)。

超过半数受访者(59%)认为需要接受过专业培训的人来审核此类患者招募。

值得关注的是,在做出回应的92位受访者中,只有20位自己使用了Twitter,LinkedIn,Doximity和YouTube等社交媒体招募患者。

分析使用社交媒体进行癌症患者招募的研究者特征可以发现,与旁观者相比,参与者可能更年轻(45岁或以下,40% vs 21%),可分配超过30%的工作时间专注于研究(80% vs 57%)。

与参与者相比,旁观者则更担心错误信息(68%vs 30%),误解(67%vs 25%),未披露的利益冲突(44%vs 15%)以及侵犯患者隐私权(38%vs 5%)。

尽管如此,这项调查研究的第一作者Sedrak表示,有些患者完全有能力通过社交媒体了解试验信息并与研究人员互动。

“今天,许多患者对疾病和整体治疗前景有着深刻的理解,他们在社交媒体上的活跃使得围绕癌症临床试验的讨论变得更加轻松。我们需要进行更多有关研究,以了解如何与这些不断壮大的线上患者社群进行有效沟通,在整个研究过程中与患者建立并维持可信赖的伙伴关系。”

其实,早在2013年,SWOG就成立了一个工作组,目标是使用Twitter为主的社交媒体(@SWOG,#SWOGOnc)加快临床试验招募进程。其中,转化注册研究转移性乳腺癌(MBC)项目就是一个引人注目的成功案例。

在2015年至2016年的短短7个月内,研究者招募到来自50个州的2000多名患者,并收集了生物学样本和病历。有专家评论说,得益于社交媒体推广的效应,这是“令人难以置信的快速入组”。

其他正在进行的肿瘤注册项目,包括转移性前列腺癌项目和血管肉瘤项目,分别由波士顿的达纳-法伯癌症研究所(DFCI)和布罗德研究所管理,也在使用社交媒体招募患者。

然而,也有专家提示,试验注册的最佳实践仍在研究之中。尽管已经得到长期使用,社交媒体仍然是新兴的技术和平台。MBC项目等注册研究的成功可能不适用于涵盖疗效、不良事件、随机化等其他问题的癌症治疗性临床试验。

众所周知,癌症治疗试验在吸引受试者方面存在问题,大多数患者都受到结构性问题和临床障碍的限制。Sedrak说:“在所有癌症患者中,56%的患者没有本地可及的试验,而在其余患者中,21%没有资格参与试验。”

文章结尾处写道,全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。

原始出处:

Mina S. Sedrak, et al. Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. JAMA Netw Open. 2020; 3(12):e2031202. doi: 10.1001/jamanetworkopen.2020.31202.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-03-10 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-11-18 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-01-22 fengyi818
  6. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-01-20 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1734294, encodeId=2a231e34294b5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 10 18:35:52 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728786, encodeId=48301e28786ff, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Nov 18 14:35:52 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289700, encodeId=d1071289e0087, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548558, encodeId=fcdf1548558da, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603459, encodeId=510a1603459d8, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Fri Jan 22 06:35:52 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036405, encodeId=fef9103640588, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Jan 20 18:35:52 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918467, encodeId=e41d91846edb, content=全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Wed Jan 20 16:55:36 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-01-20 Jessie Zhang

    全球有超过29亿人定期使用社交媒体平台,他们的参与创造了以前所未有的速度、覆盖范围和渗透率传播健康信息的潜能。如果克服了研究者的阻力,社交媒体可能会成为促进临床试验招募的重要工具。

    0

相关资讯

Ann Oncol:G-CSF+化疗可显著改善癌症患者的总生存期?

发表于《Ann Oncol》上的一项研究,考察了使用癌症化疗和粒细胞集落刺激因子(G-CSF)治疗恶性肿瘤,二次复发的总生存期和风险。

2018 SIMI意见书:癌症患者静脉血栓栓塞的预防和治疗

2018年10月,意大利内科学会(SIMI)发布了癌症患者静脉血栓栓塞的预防和治疗意见书,癌症患者发生血栓事件风险较高,包括静脉血栓栓塞(深静脉血栓形成),肺栓塞和动脉血栓形成。本文主要内容涉及癌症相关静脉血栓栓塞的发病机制,流行病学,一级预防和抗凝策略,出血并发症的管理等。

2019 AHA科学声明:癌症患者和生存者心脏-肿瘤康复管理心血管结局

2019年4月,美国心脏协会(AHA)发布了癌症患者和生存者心脏-肿瘤康复管理心血管结局的科学声明。心血管疾病是癌症患者早期死亡的竞争性原因,本文主要介绍了心脏肿瘤康复的相关内容,百科新功能不全的高危肿瘤患者的识别以及管理等。

癌症患者可以生孩子吗?对孩子有什么影响?

有时候,人生真的是挺残忍的,有的女性在怀孕期间,却被诊断为癌症,那么,这个时候,就陷入了纠结,到底这个孩子能不能要,那么,癌症患者可以生孩子吗?下面我们一起来了解一下吧。

2018 JSPM临床指南:癌症患者泌尿系统症状的治疗建议

2018年10月,日本姑息医学会(JSPM)发布了癌症患者泌尿系统症状的治疗建议指南,泌尿系统症状,例如肉眼血尿、上尿路症状以及膀胱疼痛常见于晚期癌症患者。本文总结了癌症患者出现泌尿系统症状的临床管理建议。

2019 AIOM/SIN共识意见:慢性肾病或血液透析的癌症患者的靶向治疗管理

2019年5月,意大利肿瘤医学协会(AIOM)联合意大利肾病学会(SIN)共同发布了慢性肾病或血液透析的癌症患者的靶向治疗管理共识。新型生物抗癌药物的出现明显改善了许多癌症患者的结局,但关于这些药物在慢性肾病和血液透析患者中的疗效、安全性以及药代动力学的数据有限,本文主要针对这类患者的靶向治疗管理提出共识意见。